- NeoStem (NBS) obtains worldwide licensing rights to three families of patents from the University of California, San Francisco, providing the company with "incremental protection" for its human Regulatory T cell ("Treg") platform.
- The IP cover Treg's potential for treating autoimmune disorders, including Type 1 diabetes.
- NeoStem's IP for Treg includes the rights to use 22 patents in the U.S. and other major regions. (PR)
at Zacks.com (Nov 18, 2014)